OBJECTIVES: To examine and compare costs and cost drivers for various metastatic renal cell carcinoma (mRCC) drugs. METHODS: This retrospective cohort study used administrative healthcare claims from MarketScan® Commercial and Medicare Supplemental Databases to identify patients newly diagnosed with mRCC (index event) from 1/1/2006 to 3/31/2014, with continuous health plan enrollment at least 6 months prior to and 30 days following the index date. Treatment with approved mRCC products on or after the index date was required. Patients were followed until death, health plan enrollment end, initiation of non-mRCC chemotherapy, or study end. Healthcare costs reflect paid amounts to providers and out-of-pocket costs to patients. Bootstrapping was used to determine differences between costs of drugs. RESULTS: The study population included 3060 mRCC patients. Total per-patient-per-month costs for pazopanib ($14,486) and sorafenib ($13,841) were not statistically lower at an alpha level of 0.05 than sunitinib ($15,808). However, temsirolimus ($19,431) and IL-2 ($96,619) were significantly more costly than sunitinib. For inpatient and patient out-ofpocket costs, IL-2 was significantly more costly than sunitinib. Outpatient costs of pazopanib and temsirolimus were both significantly more costly than sunitinib while sorafenib was significantly less costly. Multivariate modeling found that year of index date, number of metastatic sites, NCI comorbidity index score, and evidence of an adverse event during first line treatment were significantly associated with greater costs for all patients. In general, approximately 46% of total costs were specific to mRCC drug costs while 30% were due to inpatient stay. CONCLUSIONS: This study demonstrates that there may be significant cost differences between mRCC drugs and that mRCC drug costs represent the largest driver of total healthcare costs in this patient population. Further research on comparative effectiveness, weighing costs relative to clinical benefit, is needed.
OBJECTIVES: Colorectal cancer (CRC) is a major cause of morbidity and mortality worldwide. Approximately 25% of patients present metastatic disease at diagnosis and about 50% will develop metastatic disease. Patients with metastatic colorectal cancer (mCRC) and wild-type or mutated KRAS are eligible for sequential treatments, including monoclonal antibodies as first or second-line regimens. Use of bevacizumab (Bev) through multiple lines (TML) may benefit patients with mCRC. Considering the emerging data, it is important to understand these implications in terms of costs for the Brazilian private healthcare system. Our objectives were to compare economic outcomes of different sequences of therapy including monoclonal antibodies for the treatment of mCRC. METHODS: Eight scenarios were analyzed, each one comparing different treatment sequences. A sequence of bevacizumab TML (first-line and beyond first progression) was compared in each scenario with another sequence without bevacizumab TML. To compare the economic outcomes, the monthly cost and the total cost of the sequence per patient were calculated, according to the first, second and third-lines combinations. RESULTS: Considering a standard time of treatment of 12.8 months and progression-free survival (PFS) varying from 17.0 to 20.6, all scenarios with bevacizumab TML were less costly than multiple lines without bevacizumab. The lowest monthly cost was related to bevacizumab TML (1stline bevacizumab 5mg+FOLFOX → 2ndline bevacizumab 5mg+FOLFIRI → 3rdline best supportive care [BSC] ). This sequence represents a monthly cost of R$ 18,192.41 per patient while the same scenario with cetuximab in first-line (1stline cetuximab 250mg+FOLFIRI → 2ndline bevacizumab 10mg+FOLFOX → 3rdline BSC) represents R$ 23,640.57 per month/ patient. CONCLUSIONS: Use of bevacizumab TML for mCRC is less costly compared with sequences of biological therapy that starts with cetuximab in the first-line followed by bevacizumab in second-line treatment. Resource savings with sequential bevacizumab have the potential to optimize third-line treatment strategy for mCRC patients with wild-type KRAS in Brazil. ,390) , 23,246 RMB (±15,545), respectively. There was a signifi-chronic pulmonary disease. The sunitinib cohort had less time between diagnosis and index prescription than the pazopanib cohort (334 vs. 422 days; p= 0.037). Proportions of patients with treatment continuation, discontinuation, switching, or interruption were NS different. Before imputation, adjusted mean [SD] daily medication costs during persistence were higher for sunitinib ($218.19 [34.73] vs. $177.07 [45.76] ; p< 0.0001), but NS different after imputation (sunitinib $181.41 [22.34] vs. pazopanib $175.77 [44.26] ; p= 0.213). Twelve-month adjusted RCC-related medical costs were significantly lower for sunitinib than pazopanib before imputation ($36,638.96 [$25,199.38] vs. $45,219.75 [$34,828 .70], p= 0.021) and after imputation ($36.393.90 [$26,543.89] vs. $45,652.99 [$35,226 .83], p= 0.015. The RCC-related prescription costs were NS different between the two drugs before and after imputation. CONCLUSIONS: Treatment patterns and persistence with sunitinib or pazopanib were NS different. Sunitinib daily cost was NS different from pazopanib after imputation. Further analysis is needed regarding dosing schedule, days supply, and related calculations. OBJECTIVES: The study aimed to (1) develop a cost model for colonoscopy preparation among patients referred for colonoscopy using split-dose reduced-volume oral sulfate solution (OSS) and generic polyethylene glycol with electrolytes solution (PEG-ELS), (2) examine cost-savings associated with OSS versus PEG-ELS, and (3) assess the robustness of the cost model. METHODS: Clinical efficacy of each agent was based on the results of a 541-patient clinical trial comparing OSS to PEG-ELS. Cleansing agent and colonoscopy procedure costs were calculated from OptumHealth Reporting & Insights claims data for 2010-Q12013. In the cost model, patients' colonoscopies were tracked until the patient reached age 75. The difference per patient per year (PPPY) in total cleansing agent and colonoscopy procedure costs over the time horizon between the OSS and PEG-ELS cohort was calculated. One-way sensitivity analyses were also conducted to test the robustness of the cost model. RESULTS: The cost model showed that OSS patients had fewer colonoscopies over the time horizon (OSS: 0.158 vs. PEG-ELS: 0.170 PPPY). Total PPPY costs were $280.34 for the OSS cohort and $296.36 for the PEG-ELS cohort, resulting in a cost-saving of $16.01 to the payer for the OSS cohort. Varying the annual colonoscopy completion rate, surveillance intervals, time horizon, and proportion of high risk patients did not change the observation of cost-savings under OSS. Cost-savings switched from the OSS to the PEG-ELS cohort in three cases: (1) base-case cost of a completed colonoscopy decreased by 75%, (2) basecase cost of OSS increased to over $143 per usage, and (3) all non-completers were lost to follow up. CONCLUSIONS: From a payer's perspective, the cost model showed that the use of OSS as the cleansing agent resulted in potential costsavings compared with PEG-ELS. The cost model was robust and cost-savings under OSS remained under various sensitivity analyses.
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